To determine whether insulin glulisine decreases the breakfast post prandial glycemic excursion in comparison to insulin aspart.
This is a treatment, open label, crossover study comparing two and four hour breakfast post prandial blood glucose levels after receiving a dose of insulin glulisine or insulin aspart administered subcutaneously and consuming the breakfast meal from a prescribed menu containing 45, 60 or 75 grams of carbohydrate. Each subject will receive insulin glulisine for ten days and insulin aspart for ten days.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
16
Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days
Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
Helen DeVos Childrens Hospital
Grand Rapids, Michigan, United States
Difference in the Two Hour and Four Hour Post Prandial Blood Glucose Levels Following Administration of Insulin Glulisine Versus Insulin Aspart at the End of the Twenty Study Days
Compare average blood glucose at 2 and 4 hours post prandial minus blood glucose at baseline (prior to eating)
Time frame: measured daily at baseline, 2 and 4 hours post prandial for 20 days
Occurrence of Hypoglycemia;
Time frame: measured daily at 2 and 4 hours postprandial for 20 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.